- Home
- ASND vs DVA Comparison
ASND vs DVA Comparison
Compare ASND & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- DVA
- Stock Information
- Founded
- ASND 2006
- DVA 1994
- Country
- ASND Denmark
- DVA United States
- Employees
- ASND N/A
- DVA N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- DVA Misc Health and Biotechnology Services
- Sector
- ASND Health Care
- DVA Health Care
- Exchange
- ASND Nasdaq
- DVA Nasdaq
- Market Cap
- ASND 9.1B
- DVA 10.9B
- IPO Year
- ASND 2015
- DVA 1995
- Fundamental
- Price
- ASND $157.54
- DVA $139.56
- Analyst Decision
- ASND Strong Buy
- DVA Hold
- Analyst Count
- ASND 16
- DVA 4
- Target Price
- ASND $213.88
- DVA $159.75
- AVG Volume (30 Days)
- ASND 575.6K
- DVA 827.0K
- Earning Date
- ASND 05-01-2025
- DVA 05-12-2025
- Dividend Yield
- ASND N/A
- DVA N/A
- EPS Growth
- ASND N/A
- DVA 14.90
- EPS
- ASND N/A
- DVA 10.11
- Revenue
- ASND $398,509,511.00
- DVA $12,968,524,000.00
- Revenue This Year
- ASND $72.24
- DVA $5.65
- Revenue Next Year
- ASND $76.59
- DVA $3.65
- P/E Ratio
- ASND N/A
- DVA $14.19
- Revenue Growth
- ASND 12.06
- DVA 5.11
- 52 Week Low
- ASND $111.09
- DVA $131.44
- 52 Week High
- ASND $183.00
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- ASND 48.49
- DVA 40.76
- Support Level
- ASND $151.11
- DVA $136.43
- Resistance Level
- ASND $165.26
- DVA $147.10
- Average True Range (ATR)
- ASND 7.83
- DVA 3.53
- MACD
- ASND -1.28
- DVA 0.24
- Stochastic Oscillator
- ASND 20.71
- DVA 29.29
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.